BioCentury | Nov 22, 2019
Finance

Syncona backs Cambridge oncology spinout Azeria in £32M series B

...Azeria is the first company in which Syncona has followed an indirect investment via the CRT Pioneer Fund...
...Azeria is the first company in which Syncona has followed an indirect investment via the CRT Pioneer Fund...
BioCentury | Nov 21, 2019
Clinical News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

...Azeria is the first company in which Syncona has followed an indirect investment via the CRT Pioneer Fund...
...Azeria is the first company in which Syncona has followed an indirect investment via the CRT Pioneer Fund...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...Redmile Group. The company raised a £28.3 million ($36.3 million) series A round from Syncona, CRT Pioneer Fund...
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

...The company raised a £28.3 million ($36.3 million) series A round in 2016 from Syncona, CRT Pioneer Fund...
BioCentury | Jan 18, 2019
Emerging Company Profile

Achilles’ truncal neoantigens

...partners: None Number of employees: 50 Funds raised: £28.3 million ($36.3 million) Investors: Syncona Ltd., CRT Pioneer Fund...
BioCentury | Sep 1, 2017
Financial News

Macrophage raises L3M to close L12M series A

...Merck Ventures in the final tranche of a £12 million ($15.4 million) series A round. CRT Pioneer Fund...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...$24.3M) Small molecules to reprogram adult stem cells in situ Gene/Cell therapy; Neurology; Cardiovascular Preclinical CRT Pioneer Fund...
...U.K. DNA damage repair Cancer Research UK Cancer AbbVie Ventures ; Arix Bioscience plc (LSE:ARIX); CRT Pioneer Fund...
...Stevenage, U.K. Immunotherapies targeting truncal tumor neo-antigens University College London ; Francis Crick Institute Cancer CRT Pioneer Fund...
BioCentury | Apr 18, 2017
Financial News

Cancer Research UK, NCI funding Ras research

...to target Ras, as well as screens and assays to identify potential drug candidates. The CRT Pioneer Fund...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
BioCentury | Jan 12, 2017
Financial News

Macrophage completes venture financing

...Macrophage raised £9 million ($11 million) in a series A round led by CRT Pioneer Fund. Novo Seeds...
Items per page:
1 - 10 of 31
BioCentury | Nov 22, 2019
Finance

Syncona backs Cambridge oncology spinout Azeria in £32M series B

...Azeria is the first company in which Syncona has followed an indirect investment via the CRT Pioneer Fund...
...Azeria is the first company in which Syncona has followed an indirect investment via the CRT Pioneer Fund...
BioCentury | Nov 21, 2019
Clinical News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

...Azeria is the first company in which Syncona has followed an indirect investment via the CRT Pioneer Fund...
...Azeria is the first company in which Syncona has followed an indirect investment via the CRT Pioneer Fund...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

...Redmile Group. The company raised a £28.3 million ($36.3 million) series A round from Syncona, CRT Pioneer Fund...
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

...The company raised a £28.3 million ($36.3 million) series A round in 2016 from Syncona, CRT Pioneer Fund...
BioCentury | Jan 18, 2019
Emerging Company Profile

Achilles’ truncal neoantigens

...partners: None Number of employees: 50 Funds raised: £28.3 million ($36.3 million) Investors: Syncona Ltd., CRT Pioneer Fund...
BioCentury | Sep 1, 2017
Financial News

Macrophage raises L3M to close L12M series A

...Merck Ventures in the final tranche of a £12 million ($15.4 million) series A round. CRT Pioneer Fund...
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...$24.3M) Small molecules to reprogram adult stem cells in situ Gene/Cell therapy; Neurology; Cardiovascular Preclinical CRT Pioneer Fund...
...U.K. DNA damage repair Cancer Research UK Cancer AbbVie Ventures ; Arix Bioscience plc (LSE:ARIX); CRT Pioneer Fund...
...Stevenage, U.K. Immunotherapies targeting truncal tumor neo-antigens University College London ; Francis Crick Institute Cancer CRT Pioneer Fund...
BioCentury | Apr 18, 2017
Financial News

Cancer Research UK, NCI funding Ras research

...to target Ras, as well as screens and assays to identify potential drug candidates. The CRT Pioneer Fund...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
BioCentury | Jan 12, 2017
Financial News

Macrophage completes venture financing

...Macrophage raised £9 million ($11 million) in a series A round led by CRT Pioneer Fund. Novo Seeds...
Items per page:
1 - 10 of 31